Loading clinical trials...
Loading clinical trials...
A Multicenter, Open-Label, Randomized-Controlled Study of Abemaciclib, a CDK4 and 6 Inhibitor, in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer With Visceral Metastases
Conditions
Interventions
Abemaciclib
Fulvestrant
+1 more
Locations
61
United States
Scottsdale Healthcare Hospitals
Avondale, Arizona, United States
University of Arizona Cancer Center
Phoenix, Arizona, United States
Yuma Regional Cancer Center
Yuma, Arizona, United States
CARTI Cancer Center
Little Rock, Arkansas, United States
Comprehensive Blood and Cancer Center
Bakersfield, California, United States
Compassionate Cancer Care Medical Group Inc
Corona, California, United States
Start Date
August 14, 2019
Primary Completion Date
August 11, 2020
Completion Date
August 11, 2020
Last Updated
August 24, 2021
NCT05660083
NCT07354022
NCT02422641
NCT06625775
NCT06649331
NCT07203729
Lead Sponsor
Eli Lilly and Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions